Stentys Concludes Clinical Trial Ahead of Plan  
2/2/2012 7:19:38 AM

PRINCETON, N.J. & PARIS--(BUSINESS WIRE)--STENTYS S.A. (STNT.PA), a medical technology company commercializing the world's first and only Self-Apposing™ Stent to treat Acute Myocardial Infarction (AMI), announced today that the “APPOSITION III” clinical study successfully enrolled 1,000 patients suffering from a severe heart attack and that the final results of the examination 30 days after treatment will be presented during the upcoming EuroPCR international cardiology congress.